Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 13/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.54 |
| ▸ | DRD2 | P14416 | 10/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10107827 | 0.92 | DRD3 (0.57) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL6003466 | 0.89 | DRD3 (0.51) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL6002380 | 0.85 | DRD2 (0.48) | DRD3KCNH2DRD2 | |
| SCHEMBL13089084 | 0.84 | DRD3 (0.55) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL378256 | 0.84 | DRD3 (0.55) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL919354 | 0.84 | DRD3 (0.55) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL14606013 | 0.84 | DRD3 (0.55) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL13007625 | 0.84 | DRD3 (0.55) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL4074941 | 0.83 | KCNH2 (0.43) | DRD3KCNH2DRD2 | |
| Hydrochloric Acid SCHEMBL5447866 | 0.82 | KCNH2 (0.42) | DRD3KCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | DOV PHARMACEUTICAL, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | HTR1B, SLC6A3, CYP1B1 | DRD3 239/4885KCNH2 936/4885DRD2 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.